Patents by Inventor William Mongan
William Mongan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240252389Abstract: A deep vein thrombosis prevention device (DVT-PD) is a wearable device for the lower extremities senses the user's dynamic or static movements and actuates accordingly to lower DVT risks. The device uses a comprehensive control system together with an integrated machine learning model. to classify, manage, direct, and regulate signals and the behavior of the device.Type: ApplicationFiled: May 16, 2022Publication date: August 1, 2024Applicant: Drexel UniversityInventors: Hassan El Mghari, Gregory Olsen, Zikang Ling, Srivatsa Rayar Ganesh, William Mongan, Vasil Pano, Kapil R. Dandekar
-
Publication number: 20240212818Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 1, 2022Publication date: June 27, 2024Inventors: Judy FIROR, Howard Hutchinson, William Mongan, Richard L. Skelly, Jerry Valentine, Merrill Zavod
-
Patent number: 12002558Abstract: A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.Type: GrantFiled: August 29, 2022Date of Patent: June 4, 2024Assignee: ASTRAZENECA UK LIMITEDInventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Patent number: 11972844Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: GrantFiled: May 18, 2021Date of Patent: April 30, 2024Assignee: ASTRAZENECA UK LIMITEDInventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Publication number: 20230005584Abstract: A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.Type: ApplicationFiled: August 29, 2022Publication date: January 5, 2023Inventors: James BLASETTO, Judy FIROR, David GUIGA, William MONGAN, Robert PRYBOLSKY, Richard L. SKELLY
-
Patent number: 11430555Abstract: A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.Type: GrantFiled: December 23, 2020Date of Patent: August 30, 2022Assignee: ASTRAZENECA UK LIMITEDInventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Publication number: 20210272660Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: ApplicationFiled: May 18, 2021Publication date: September 2, 2021Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Patent number: 11031104Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: GrantFiled: February 14, 2020Date of Patent: June 8, 2021Assignee: ASTRAZENECA UK LTD.Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Publication number: 20210118540Abstract: A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.Type: ApplicationFiled: December 23, 2020Publication date: April 22, 2021Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Patent number: 10910091Abstract: A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.Type: GrantFiled: May 11, 2020Date of Patent: February 2, 2021Assignee: AstraZeneca UK Ltd.Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Publication number: 20200372989Abstract: A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.Type: ApplicationFiled: May 11, 2020Publication date: November 26, 2020Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Publication number: 20200294631Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: ApplicationFiled: February 14, 2020Publication date: September 17, 2020Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Patent number: 10600502Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: GrantFiled: December 20, 2016Date of Patent: March 24, 2020Assignee: AstraZeneca UK Ltd.Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Patent number: 10325678Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: GrantFiled: January 22, 2018Date of Patent: June 18, 2019Assignee: AstraZeneca UK Ltd.Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Publication number: 20180197622Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: ApplicationFiled: January 22, 2018Publication date: July 12, 2018Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
-
Publication number: 20180173855Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.Type: ApplicationFiled: December 20, 2016Publication date: June 21, 2018Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly